the AUC, sensitivity and the specificity were 0.984 (higher than 0.978 of CA125 alone) (Figure 4d), 97.66% (higher than 89.84% of CA125 alone), 87.50% (Figure 4g and Table 3) for normal versus ovarian tumor (N = 168); 0.896 (Figure 4e), 86.36%, 78.57% (Figure 4h and Table 3) for benign versus malignant (borderline + malignant) (N = 36); 0.836 (higher than 0.807 of CA125 alone) (Figure 4f), 80.26%, 71.43% (higher than 42.86% of CA125 alone) (Figure 4i and Table 3) for borderline versus malignant (N = 83), respectively. This evidence concerns the gene MUC16 and ovarian neoplasm.